Luminate Health Alternatives for Clinical Laboratories: Solia Direct vs. Luminate Health for DTC Testing in 2026

For established clinical laboratories evaluating direct-to-consumer testing, Luminate Health is a credible and established platform.

Its public offering extends well beyond basic results delivery. Luminate provides patient engagement, provider engagement, population-health capabilities, direct-to-consumer testing services, and an integration ecosystem. Its DTC product allows patients to browse laboratory testing, add tests to cart, pay online, and receive results, while giving laboratories tools for test-catalog and phlebotomy-order management. (Luminate Health)

So why would a laboratory search for a Luminate Health alternative?

Usually not because Luminate cannot support DTC testing.

The more important reason is that laboratories can be solving different strategic problems.

A laboratory primarily focused on improving patient access to results, longitudinal laboratory data, provider engagement, and population-health intelligence may place Luminate high on its shortlist.

A laboratory trying to build a broader owned consumer diagnostics business may place more emphasis on commerce, catalog and pricing control, collection workflows, order orchestration, operational administration, recurring testing, memberships, and the ability to configure the complete consumer channel around its existing laboratory infrastructure.

That is the distinction Solia Direct is designed around. Solia Direct publicly positions itself as a consumer operating layer for laboratories spanning commerce, scheduling and collection, patient accounts, workflow orchestration, results and longitudinal health, intelligence, and administration while sitting above existing LIS/LIMS and other clinical systems. (Solia Direct)

The short answer: Is Solia Direct an alternative to Luminate Health?

Yes—particularly for laboratories evaluating Luminate Health as part of a direct-to-consumer testing initiative.

Both platforms can help laboratories create consumer-facing digital experiences and both overlap across DTC ordering, patient results, longitudinal engagement, integrations, and laboratory modernization.

The difference is primarily their center of gravity.

Luminate Health

Publicly positions a broad laboratory platform around:

• patient engagement;
• understandable laboratory results;
• longitudinal patient records;
• provider engagement;
• patient matching and data harmonization;
• population health and disease management;
• direct-to-consumer testing;
• FHIR and other integrations. (Luminate Health)

Solia Direct

Is explicitly designed around operating the laboratory's consumer business, including:

• consumer catalog and commerce;
• pricing and promotions;
• scheduling and collection;
• patient accounts;
• order and workflow orchestration;
• laboratory integrations;
• official results;
• longitudinal health;
• repeat testing;
• memberships and alternative commercial models;
• intelligence;
• laboratory administration and operations. (Solia Direct)

A simplified distinction is:

Neither framing makes one platform universally better.

It makes them potentially better suited to different laboratory strategies.

Solia Direct vs. Luminate Health at a glance

Luminate states that its platform is used by millions of patients, has processed billions of laboratory tests, operates across all 50 states, and supports laboratories spanning more than 70,000 points of care. These are Luminate's own published scale claims and represent an important enterprise-proof advantage for an established vendor. (Luminate Health)

Solia Direct, by comparison, is a newer platform and should be evaluated primarily on architecture, fit, implementation requirements, commercial model, and its working Solia Health reference implementation rather than on equivalent historical deployment scale. (Solia Direct)

Why would a laboratory look for a Luminate Health alternative?

Searching for an alternative does not necessarily mean replacing Luminate.

Many laboratories are evaluating vendors before launching a new DTC program.

Others may already operate patient-engagement infrastructure but want to determine whether a different architecture better supports a broader consumer strategy.

The most common strategic questions are likely to be:

Do we primarily need a better patient-engagement platform?

or

Do we need an operating platform for an entire consumer diagnostics business?

That distinction affects nearly every downstream decision.

1. Consumer commerce: DTC module or core operating layer?

Luminate clearly supports direct-to-consumer commerce.

Its public DTC product allows consumers to browse a laboratory's available tests, add tests to a cart, pay online, and access results. Luminate also describes real-time test-catalog management and tools for phlebotomists to manage patient orders at collection. (Luminate Health)

That is a legitimate end-to-end DTC capability.

Solia Direct approaches commerce as one of the foundational layers of the platform.

Products are modeled around laboratory testing rather than generic ecommerce inventory and can connect to:

• tests and panels;
• biomarkers;
• pricing;
• member pricing;
• promotions;
• geographic availability;
• specimen requirements;
• collection eligibility;
• checkout;
• payment status;
• downstream laboratory workflow. (Solia Direct)

This distinction becomes increasingly important when the laboratory wants to operate more than a simple:

test → purchase → result

model.

For example, a laboratory may eventually want:

• à-la-carte testing;
• curated diagnostic programs;
• recurring testing;
• member pricing;
• memberships;
• hybrid commercial models;
• different collections by geography;
• promotions;
• consumer merchandising;
• multiple branded deployments.

Solia Direct publicly supports multiple commercial models on the same underlying platform. (Solia Direct)

When this matters

If the laboratory views DTC primarily as an additional ordering channel, both platforms deserve evaluation.

If the laboratory views DTC as a new consumer business line, deeper commerce and business-model configuration become more strategically important.

2. Collection and operational workflow

A consumer transaction is only useful if it becomes a correctly ordered, collected, accessioned, tested, and resulted specimen.

This is where DTC software becomes materially different from ordinary ecommerce.

Luminate publicly describes phlebotomist tools for managing patient DTC orders and integrations for scheduling and other services. (Luminate Health)

Solia Direct makes scheduling and collection a named core platform capability and supports configuration around laboratory locations, scheduled collection, walk-in collection, mobile or at-home collection, workplace collection, collection networks, and self-collection where supported. (Solia Direct)

More importantly, Solia positions workflow orchestration as its own platform layer.

The intention is to represent the states between commerce and the official laboratory result:

along with exceptions.

Those exceptions matter.

A production laboratory workflow eventually encounters:

• payment failure;
• incomplete provider authorization;
• no-show;
• specimen rejection;
• recollection;
• delayed results;
• amended results;
• refunds;
• integration failures;
• patient matching problems.

A laboratory evaluating either platform should therefore ask the vendor to demonstrate the failure states, not simply a successful checkout.

3. LIS/LIMS integration: what actually connects?

Both platforms publicly emphasize interoperability.

Luminate offers a documented integration ecosystem that includes:

• FHIR API services;
• EMPI integrations;
• scheduling integrations;
• billing integrations;
• identity verification;
• single sign-on. (Luminate Health)

Luminate also describes patient-matching algorithms, longitudinal data structuring, data harmonization, and related IT services. (Luminate Health)

These are meaningful capabilities, particularly for laboratories dealing with large historical patient populations and fragmented laboratory data.

Solia Direct publicly describes an architecture in which the consumer platform sits above:

through:

The clinical laboratory system remains the source of truth for official testing and results.

The checkbox “LIS integration” is not enough

During vendor evaluation, ask exactly what moves across the interface:

• patient demographics?
• consumer order?
• requisition?
• test codes?
• accession number?
• specimen state?
• partial results?
• final results?
• corrected results?
• amended results?
• collection status?
• cancellation?

Then ask:

What happens when the interface fails?

A platform's real value is determined as much by exception handling as by the initial API connection.

4. Patient engagement and results: Luminate's established strength

This is an area where Luminate deserves substantial credit.

Luminate's patient-engagement application organizes laboratory data into health categories, disease- and condition-specific views, and health summaries. It places educational content beside results and structures laboratory data into longitudinal records with trends, graphs, and notifications. (Luminate Health)

The company also describes patient matching across hundreds of millions of laboratory records and capabilities for structuring, harmonizing, and cleansing laboratory data. (Luminate Health)

This is much more sophisticated than simply delivering a PDF.

For laboratories whose primary objective is:

give patients better access to laboratory information, help them understand it, and build engagement around that data,

Luminate has a strong and established public proposition.

Solia Direct's approach

Solia Direct also treats results and longitudinal health as a core platform capability.

Its platform is designed around:

• official results;
• biomarker trends;
• historical results;
• longitudinal health;
• repeat testing;
• guided education and navigation. (Solia Direct)

The difference is that these capabilities are positioned as one stage within the larger consumer lifecycle.

For a laboratory evaluating the two platforms, the question is not whether either vendor supports patient results.

Both do.

The question is how much of the overall consumer operating model needs to exist around those results.

5. Provider engagement: an area where Luminate may be the stronger fit

Luminate offers a dedicated provider-engagement application.

Its public product includes:

• access to a patient's community laboratory record;
• result history;
• new-result notifications;
• critical-value notifications;
• provider notes;
• real-time access;
• analytics;
• scorecards;
• risk stratification. (Luminate Health)

That is a significant capability.

If the laboratory's digital strategy needs to simultaneously strengthen:

consumer relationships + physician-client relationships + health-system relationships,

Luminate's provider offering should receive serious consideration.

Solia Direct can support provider-related workflows as part of laboratory configurations, but its current public product positioning is much more explicitly centered on the consumer operating layer than on a standalone provider portal.

That distinction should not be hidden in a serious comparison.

6. Population health and laboratory-data intelligence

Luminate also publicly offers a dedicated population-health and disease-management capability.

The company describes structuring longitudinal records across patient populations and using clinical and business analytics to support population health, disease management, physician insights, patient satisfaction, and outcomes. (Luminate Health)

Solia Direct has an intelligence layer around laboratory, consumer, workflow, and longitudinal data, but its public positioning today is more oriented toward:

• guided test discovery;
• consumer explanation;
• navigation;
• operating intelligence;
• consumer diagnostics workflows. (Solia Direct)

For a health system laboratory where population-level clinical analytics is one of the core purchasing requirements, Luminate may therefore be the stronger initial fit based on currently public product positioning.

For a laboratory building a consumer revenue channel, Solia's commercial and operational focus may matter more.

7. Laboratory brand and customer ownership

This is strategically important for a DTC business.

Solia Direct explicitly states that the laboratory retains:

That ownership model is central to Solia's positioning.

The laboratory is not intended to become a fulfillment backend for a separate consumer diagnostics brand.

Instead, Solia Direct sits underneath the laboratory's own consumer experience.

Luminate also describes its DTC offering as a branded experience for the laboratory, where patients browse the lab's test offerings and purchase online. (Luminate Health)

Therefore, it would be inaccurate to suggest that laboratory branding exists only with Solia.

The more useful diligence questions are deeper:

• Whose domain is used?
• Who owns the consumer account relationship?
• Who controls catalog content?
• Who controls pricing?
• Who controls communications?
• Can customer data be exported?
• Can the laboratory operate multiple brands?
• What happens to consumer data when the vendor relationship ends?
• Are consumers marketed services outside the laboratory relationship?

Those answers should be evaluated contractually and technically—not assumed from the term “white label.”

For a laboratory building a long-term consumer asset, the important question is not simply whether its logo appears on the interface.

It is:

How much of the consumer business does the laboratory actually control?

8. Pricing and total cost of ownership

Enterprise healthcare software is difficult to compare on headline price alone.

A DTC deployment may involve:

• implementation;
• configuration;
• LIS/LIMS interfaces;
• provider-order infrastructure;
• collection integrations;
• payment processing;
• identity systems;
• custom development;
• support;
• recurring software fees;
• transaction costs;
• third-party services.

Solia Direct publishes its standard platform pricing.

Current public pricing is:

Enterprise arrangements, significant custom engineering, and material third-party services remain subject to the applicable scope and commercial agreement. (Solia Direct)

Luminate's reviewed public product pages do not present equivalent standard implementation and subscription pricing.

That does not mean one model is necessarily more or less expensive.

Enterprise pricing can depend heavily on:

• laboratory size;
• patient volume;
• integrations;
• products deployed;
• implementation scope;
• support;
• transaction structure;
• contract length.

Compare total operating cost, not subscription price

A lower software fee can become expensive if the laboratory has to fund:

• custom integrations;
• manual order reconciliation;
• internal engineering;
• multiple point solutions;
• additional administrative staff;
• ongoing customization.

A higher software fee can also be wasteful if the organization purchases capabilities it will not use.

The appropriate comparison is:

What will it cost our laboratory to launch, operate, maintain, and evolve the complete DTC channel over three years?

Not:

Which vendor has the lower monthly software price?

For a deeper financial framework, see:

How Much Does It Cost to Launch Direct-to-Consumer Testing for an Existing Laboratory?

9. Implementation model and speed to market

A platform's feature set matters only if it can be deployed against the laboratory's real systems and workflows.

Before choosing either Solia Direct or Luminate Health, map the actual implementation.

At minimum:

Then identify every external dependency.

For example:

• physician-order network;
• collection network;
• mobile phlebotomy;
• payment processor;
• identity verification;
• scheduling system;
• communications provider;
• laboratory interfaces.

Ask for an implementation map before signing

A credible vendor should be able to explain:

• What is already part of the platform?
• What must be configured?
• What must be integrated?
• What requires custom development?
• What depends on a third party?
• What does the laboratory itself need to provide?
• Who owns each integration after launch?
• What is included in the commercial agreement?
• What creates additional cost?
• What specifically defines production readiness?

A polished demo does not answer those questions.

The implementation architecture does.

10. When Luminate Health may be the better fit

A credible Luminate Health alternatives guide should be explicit about where Luminate may have the stronger proposition.

Based on its current public product positioning, Luminate deserves particularly serious consideration when the laboratory's primary objectives include:

Patient engagement as the central strategy

Luminate has substantial public emphasis on helping patients access, organize, understand, and track laboratory results longitudinally. (Luminate Health)

Provider engagement

Luminate has a dedicated provider product with laboratory-record access, notifications, critical-value communication, notes, analytics, and related functionality. (Luminate Health)

Population health

Its public portfolio includes population-health and disease-management capabilities beyond the immediate DTC transaction. (Luminate Health)

Large-scale patient-data normalization

Luminate publicly emphasizes patient matching, laboratory-data structuring, harmonization, and longitudinal record construction.

Established enterprise deployment history

Luminate states that it serves millions of patients, has processed billions of results, operates nationwide, and supports laboratories across tens of thousands of points of care. (Luminate Health)

That deployment history is materially stronger than Solia Direct's today.

If those capabilities and enterprise proof are the primary evaluation criteria, Luminate may be the more appropriate choice.

11. When Solia Direct may be the stronger fit

Solia Direct becomes particularly relevant when the laboratory's strategic objective is broader:

Build and operate our own consumer diagnostics business.

That means the laboratory wants more than improved digital results.

It wants to control the complete commercial lifecycle.

Consumer commerce is strategically important

The laboratory wants to configure:

• its own test catalog;
• panels;
• pricing;
• promotions;
• memberships;
• recurring programs;
• collection eligibility;
• geographic availability;
• commercial models.

The DTC channel needs to connect directly to operations

The laboratory wants:

to operate as a connected system rather than separate software experiences.

The existing LIS/LIMS should remain underneath

Solia Direct is explicitly architected as a consumer layer above existing laboratory infrastructure rather than an LIS/LIMS replacement. (Solia Direct)

The laboratory wants to own the consumer relationship

The brand, domain, catalog, pricing, and consumer relationship remain centered on the laboratory. (Solia Direct)

Repeat testing and new commercial models matter

Solia Direct supports the consumer journey beyond the first result through longitudinal tracking, repeat testing, programs, and configurable membership or recurring models.

Operational administration matters as much as patient UX

Solia Direct treats admin and operations as part of the platform rather than focusing exclusively on the consumer-facing experience.

For a laboratory trying to create a consumer business that competes with modern diagnostics companies while using its own underlying testing infrastructure, those capabilities become strategically important.

Luminate Health versus Solia Direct: the core decision

A useful way to frame the choice is this:

Choose around the problem you are trying to solve.

If the problem is primarily:

“We need a highly mature digital engagement layer around laboratory data for patients and providers.”

Luminate Health deserves serious consideration.

If the problem is primarily:

“We want to turn our existing laboratory infrastructure into a modern, owned consumer diagnostics business.”

Solia Direct deserves serious consideration.

There is substantial overlap between the platforms.

The difference is where each product currently places its strongest emphasis.

That is more useful than pretending one vendor wins every feature comparison.

What if your laboratory already uses Luminate Health?

Searching for a Luminate Health alternative does not necessarily mean that replacing Luminate is the correct decision.

An existing deployment may already be deeply integrated into:

• patient identity;
• results delivery;
• provider workflows;
• laboratory data;
• communications;
• enterprise systems.

Replacing functioning infrastructure creates its own cost and risk.

The first question should therefore be:

What strategic or operational requirement is the existing platform not meeting?

Possible answers might include:

• deeper consumer commerce;
• different business models;
• more control over merchandising;
• additional collection workflows;
• different operational tooling;
• a broader consumer operating layer;
• cost structure;
• customization requirements.

Only after defining the gap should a laboratory evaluate replacement.

Could Solia Direct coexist with existing laboratory infrastructure?

Yes. That is a fundamental part of the Solia architecture.

Solia Direct is designed to sit above existing LIS/LIMS, collection, scheduling, payment, and clinical systems rather than requiring the laboratory to replace its clinical infrastructure. (Solia Direct)

Whether Solia Direct should coexist with an existing patient-engagement platform such as Luminate would be deployment-specific.

The laboratory would need to define:

• which system owns consumer identity;
• which system presents results;
• which system manages commerce;
• which system manages workflow;
• whether overlapping functionality creates unnecessary duplication;
• how information moves between systems.

Running two platforms is not automatically an advantage.

The architecture should have clear system boundaries.

Questions to ask before choosing Luminate Health or an alternative

Do not select either platform from the website alone.

Use your own laboratory architecture as the evaluation framework.

Consumer business

• Can we control our own test catalog?
• Can we control pricing?
• Can we run promotions?
• Can we create bundles?
• Can we support memberships or repeat-testing programs?
• Can we operate under our own domain and brand?

Laboratory workflow

• How does the consumer order reach our LIS/LIMS?
• How is patient identity reconciled?
• How are accessions connected to consumer orders?
• How are rejected specimens handled?
• How are recollections handled?
• How are amended results handled?

Collection

• Can we use our own patient service centers?
• Can we integrate third-party draw sites?
• Can we support mobile phlebotomy?
• Can collection options change according to geography or test?

Results

• Which system remains authoritative?
• Are results structured or document-based?
• Can patients see historical trends?
• How are amended results represented?
• How are urgent or critical workflows handled?

Provider workflows

• Is there a dedicated provider experience?
• Can provider authorization be incorporated into DTC ordering?
• Can providers view longitudinal laboratory records?
• How are critical-value communications handled?

Data

• Who controls consumer data?
• Can we export it?
• How is patient matching handled?
• What data remains if the vendor relationship ends?

Technology

• Which integrations already exist?
• Which interfaces require custom work?
• Who maintains them?
• How are integration failures monitored?
• What APIs are available?

Commercial

• What is the implementation cost?
• What is the recurring cost?
• Are there transaction fees?
• Are interfaces priced separately?
• What third-party costs should we expect?
• What happens when we change our workflow after launch?

Those questions will usually reveal more than a generic feature comparison.

Ask both vendors to demonstrate your laboratory—not their standard demo

Before making a decision, give each shortlisted platform the same scenario.

For example:

We are an established clinical laboratory with an existing LIS, 25 consumer panels, three patient service centers, a mobile-phlebotomy partner, provider authorization in states where required, and plans to offer both one-time tests and recurring programs.

Then ask the vendor to demonstrate:

1. Create a consumer panel

Show:

• biomarkers;
• laboratory mapping;
• price;
• collection requirements;
• geographic rules.

2. Place the order

Show:

3. Send it into the laboratory

Show how:

• patient demographics;
• order information;
• test codes;
• requisition;

reach the laboratory system.

4. Reject the specimen

This is one of the most revealing tests.

Ask:

• What changes in the system?
• What does the patient see?
• Who creates the recollection?
• What happens operationally?

5. Return and amend results

Show:

• initial result;
• consumer presentation;
• longitudinal history;
• corrected or amended result.

6. Change the business model

Ask the vendor to add:

• member pricing;
• recurring testing;
• another collection method;
• another geography.

The vendor that best supports the laboratory's real operating model—not the vendor with the most polished standard demonstration—is usually the more relevant choice.

Is Solia Direct a direct replacement for Luminate Health?

Potentially for some laboratory DTC use cases, but the products should not be treated as perfectly interchangeable.

There is overlap across:

• DTC testing;
• consumer ordering;
• results;
• patient engagement;
• integrations;
• longitudinal data.

But each platform also has areas of different emphasis.

Luminate has dedicated public offerings around provider engagement and population health.

Solia Direct is more explicitly centered on the complete consumer operating model from commerce through collection, workflow, results, repeat engagement, and operational administration.

A laboratory should therefore determine whether it is replacing:

a patient-engagement platform

or selecting:

the operating layer for a consumer diagnostics business.

Those are related but not identical procurement decisions.

Frequently asked questions

What are the best alternatives to Luminate Health for clinical laboratories?

The answer depends on the use case. Solia Direct is a relevant alternative for laboratories focused on building a branded DTC consumer business around existing laboratory infrastructure. TestDirectly/LigoLab is another platform to evaluate when specimen collection and laboratory workflow are central requirements, while Lifepoint Informatics offers DTC capabilities within a broader laboratory and healthcare-integration stack.

For a broader category comparison, see:

Best Direct-to-Consumer Lab Testing Platforms for Clinical Laboratories in 2026

Is Solia Direct an alternative to Luminate Health?

Yes. Solia Direct and Luminate Health overlap across direct-to-consumer ordering, patient results, longitudinal engagement, and laboratory integrations. Solia Direct differs by positioning commerce, collection, workflow orchestration, operational administration, and configurable consumer business models as core parts of the platform.

How is Solia Direct different from Luminate Health?

The main difference is product orientation. Luminate's public platform has deep emphasis on patient and provider engagement, laboratory data, population health, and DTC testing. Solia Direct is centered on the broader consumer operating layer for the laboratory—from catalog and commerce through collection, workflow, results, longitudinal engagement, and operations.

Does Luminate Health support direct-to-consumer laboratory testing?

Yes. Luminate publicly offers direct-to-consumer testing services that allow patients to browse laboratory tests, add tests to a cart, pay online, and receive results. It also provides laboratory tools for catalog and phlebotomy-order management. (Luminate Health)

Which is better for an existing clinical laboratory launching DTC: Solia Direct or Luminate Health?

It depends on the laboratory's strategic priority. Luminate may be particularly strong when patient engagement, provider engagement, longitudinal laboratory data, population health, and established enterprise deployment history are central. Solia Direct may be particularly relevant when the objective is operating a broader laboratory-owned consumer business spanning commerce, collection, workflows, results, repeat testing, and administration.

Does Solia Direct replace our LIS or LIMS?

No. Solia Direct is designed to sit above existing laboratory infrastructure and connect through APIs, HL7/FHIR, and other integration adapters. The laboratory system remains responsible for authoritative clinical testing and official results. (Solia Direct)

Can our laboratory keep its own brand with Solia Direct?

Yes. Solia Direct is designed for laboratory-branded deployments in which the laboratory controls its domain, catalog, pricing, brand, and consumer relationship. (Solia Direct)

Does Solia Direct publish pricing?

Yes. Solia Direct publishes standard implementation and subscription pricing on its pricing page. Enterprise and complex deployments are scoped per deployment. (Solia Direct)

Should we replace Luminate if we already use it?

Not automatically. Replacing functioning healthcare infrastructure creates implementation cost and risk. First identify the specific capability, commercial, operational, integration, or ownership requirement that the current architecture does not satisfy. Then determine whether replacement, coexistence, additional software, or workflow changes provide the best solution.

The larger question is not Luminate versus Solia

The real question for an established laboratory is:

What kind of digital business are we building?

If the objective is primarily to modernize how laboratory information reaches patients and providers, the requirements point in one direction.

If the objective is to create a complete direct-to-consumer diagnostics business around existing laboratory infrastructure, the requirements expand substantially.

The laboratory now needs to think about:

That is the problem Solia Direct is designed to solve.

Where Solia Direct fits

Established laboratories already possess the most difficult component of diagnostics:

the infrastructure that actually performs the testing.

Solia Direct is designed to add the consumer operating layer around that infrastructure.

The platform connects:

to the laboratory's existing clinical and operational systems. (Solia Direct)

The laboratory retains its:

For laboratories actively comparing the two platforms:

View the Complete Solia Direct vs. Luminate Health Comparison

For a broader vendor comparison:

Compare Direct-to-Consumer Laboratory Platforms

To see the consumer platform in practice:

Explore the Solia Health Reference Implementation

Or discuss how the architecture would apply to your laboratory:

Schedule a Demo

Comparison methodology

This comparison is based on publicly accessible product information reviewed on August 19, 2026.

It does not represent:

• private product demonstrations;
• confidential vendor roadmaps;
• customer-specific configurations;
• negotiated commercial proposals;
• implementation guarantees.

A capability not prominently described on a vendor's public website should not automatically be assumed to be unavailable.

Vendor-published deployment, scale, product, compliance, or performance claims should be independently validated during procurement.